LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

62.04 -0.62

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

60.99

Max

62.9

Schlüsselkennzahlen

By Trading Economics

Einkommen

-6.2M

-49M

Verkäufe

-9.1M

33M

EPS

-0.81

Gewinnspanne

-151.352

Angestellte

283

EBITDA

-9.5M

-47M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+31.52% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-174M

3.9B

Vorheriger Eröffnungskurs

62.66

Vorheriger Schlusskurs

62.04

Nachrichtenstimmung

By Acuity

34%

66%

136 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Mai 2025, 23:48 UTC

Heiße Aktien

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22. Mai 2025, 23:07 UTC

Top News

Fortescue Energy CEO to Resign in Executive Overhaul

22. Mai 2025, 23:03 UTC

Wichtige Markttreiber

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22. Mai 2025, 23:59 UTC

Market Talk

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22. Mai 2025, 23:45 UTC

Market Talk

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22. Mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

22. Mai 2025, 23:23 UTC

Market Talk

Global Energy Roundup: Market Talk

22. Mai 2025, 23:23 UTC

Market Talk

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22. Mai 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22. Mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. Mai 2025, 20:46 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22. Mai 2025, 20:39 UTC

Ergebnisse

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22. Mai 2025, 20:36 UTC

Top News

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22. Mai 2025, 20:36 UTC

Top News
Ergebnisse

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22. Mai 2025, 20:32 UTC

Top News
Ergebnisse

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22. Mai 2025, 20:27 UTC

Top News

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22. Mai 2025, 20:20 UTC

Top News

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22. Mai 2025, 20:17 UTC

Top News

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22. Mai 2025, 20:16 UTC

Ergebnisse

Intchains Group 1Q Rev $18.2M >ICG

22. Mai 2025, 20:15 UTC

Top News

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22. Mai 2025, 20:08 UTC

Top News
Ergebnisse

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22. Mai 2025, 20:05 UTC

Top News

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22. Mai 2025, 20:04 UTC

Ergebnisse

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22. Mai 2025, 20:04 UTC

Ergebnisse

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22. Mai 2025, 20:01 UTC

Ergebnisse

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22. Mai 2025, 20:01 UTC

Ergebnisse

Workday 1Q Net $68M >WDAY

22. Mai 2025, 20:01 UTC

Ergebnisse

Workday 1Q EPS 25c >WDAY

22. Mai 2025, 20:01 UTC

Ergebnisse

Workday 1Q Adj EPS $2.23 >WDAY

22. Mai 2025, 20:01 UTC

Ergebnisse

Workday 1Q Subscription Revenue $2.06B >WDAY

22. Mai 2025, 20:01 UTC

Ergebnisse

Workday 1Q Rev $2.24B >WDAY

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

31.52% Vorteil

12-Monats-Prognose

Durchschnitt 82.08 USD  31.52%

Hoch 94 USD

Tief 72 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

12

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

60 / 65.58Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

136 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.